© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 10, 749-754,
May 15, 2002
© 2002 Oxford University Press
ARTICLE |
Insulin-Like Growth Factor I, IGF-Binding Protein 3, and Lung Cancer Risk in a Prospective Study of Men in China
Affiliations of authors: S. J. London (Epidemiology Branch and Laboratory of Pulmonary Pathobiology), G. S. Travlos, R. Wilson (Environmental Toxicology Program), National Institute of Environmental Health Sciences, Research Triangle Park, NC; J.-M. Yuan, M. C. Yu, R. K. Ross, Norris Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles; Y.-T. Gao, Shanghai Cancer Institute, Shanghai, China.
Correspondence to: Stephanie London, M.D., Dr.P.H., National Institute of Environmental Health Sciences, P.O. Box 12233, MD A305, Research Triangle Park, NC 27709 (e-mail: london2{at}niehs.nih.gov).
Background: Insulin-like growth factor I (IGF-I) stimulates cell proliferation and inhibits apoptosis in the lung and other tissues by interacting with the IGF-I receptor. The major binding protein for IGF-I, insulin-like growth factor-binding protein 3 (IGFBP-3), modulates the effects of IGF-I but also inhibits cell growth and induces apoptosis independent of IGF-I and its receptor. In a prospective study of men in Shanghai, China, we examined the association between serum levels of IGF-I and IGFBP-3 and the subsequent risk of lung cancer. Methods: From 1986 to 1989, serum was collected from 18 244 men aged 4564 years living in Shanghai without a history of cancer. We analyzed IGF-I and IGFBP-3 levels in serum from 230 case patients who developed incident lung cancer during follow-up and from 740 control subjects. Results: Among 230 case patients and 659 matched control subjects, increased IGF-I levels were not associated with increased risk of lung cancer. However, for subjects in the highest quartile relative to the lowest quartile of IGFBP-3, the odds ratio (OR) for lung cancer, adjusted for smoking and IGF-I, was 0.50 (95% confidence interval [CI] = 0.25 to 1.02). When the analysis was restricted to ever smokers (184 case patients and 344 matched control subjects), the OR for lung cancer in men in the highest quartile of IGFBP-3 relative to those in the lowest quartile, adjusted for smoking and IGF-I, was 0.41 (95% CI = 0.18 to 0.92). Conclusions: In this prospective study of Chinese men, higher serum levels of IGF-I did not increase the risk of lung cancer. However, subjects with higher serum levels of IGFBP-3 were at reduced risk of lung cancer. This finding is consistent with experimental data that indicate that IGFBP-3 can inhibit cellular proliferation and induce apoptosis independent of IGF-I and the IGF-I receptor.
This article has been cited by other articles:
![]() |
A. Schaffer, A. Koushik, H. Trottier, E. Duarte-Franco, N. Mansour, J. Arseneau, D. Provencher, L. Gilbert, W. Gotlieb, A. Ferenczy, et al. Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 716 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, J. Gu, Q. Dong, M. Huang, K.-A. Do, W. K. Hong, and M. R. Spitz Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7194 - 7201. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ahn, S. J. Weinstein, K. Snyder, M. N. Pollak, J. Virtamo, and D. Albanes No Association between Serum Insulin-Like Growth Factor (IGF)-I, IGF-Binding Protein-3, and Lung Cancer Risk. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 2010 - 2012. [Full Text] [PDF] |
||||
![]() |
S Rinaldi, P H M Peeters, F Berrino, L Dossus, C Biessy, A Olsen, A Tjonneland, K Overvad, F Clavel-Chapelon, M C Boutron-Ruault, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer, June 1, 2006; 13(2): 593 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Morimoto, P. A. Newcomb, E. White, J. Bigler, and J. D. Potter Variation in Plasma Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3: Genetic Factors Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1394 - 1401. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-W. Lee, L. Ma, X. Yan, B. Liu, X.-k. Zhang, and P. Cohen Rapid Apoptosis Induction by IGFBP-3 Involves an Insulin-like Growth Factor-independent Nucleomitochondrial Translocation of RXR{alpha}/Nur77 J. Biol. Chem., April 29, 2005; 280(17): 16942 - 16948. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Lavigne, D. J Baer, H. H Wimbrow, P. S Albert, E. D Brown, J. T Judd, W. S Campbell, C. A Giffen, J. F Dorgan, T. J Hartman, et al. Effects of alcohol on insulin-like growth factor I and insulin-like growth factor binding protein 3 in postmenopausal women Am. J. Clinical Nutrition, February 1, 2005; 81(2): 503 - 507. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Voskuil, A. Vrieling, L. J. van't Veer, E. Kampman, and M. A. Rookus The Insulin-like Growth Factor System in Cancer Prevention: Potential of Dietary Intervention Strategies Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 195 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pavelic, S. Krizanac, S. Kapitanovic, L. Pavelic, M. Samarzija, F. Pavicic, S. Spaventi, M. Jakopovic, Z. Herceg-Ivanovi, and K. Pavelic The Consequences of Insulin-Like Growth Factors/Receptors Dysfunction in Lung Cancer Am. J. Respir. Cell Mol. Biol., January 1, 2005; 32(1): 65 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Gapstur, P. Kopp, B. C-H. Chiu, P. H. Gann, L. A. Colangelo, and K. Liu Longitudinal Associations of Age, Anthropometric and Lifestyle Factors with Serum Total Insulin-Like Growth Factor-I and IGF Binding Protein-3 Levels in Black and White Men: the CARDIA Male Hormone Study Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2208 - 2216. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Lavigne, H. H. Wimbrow, B. A. Clevidence, P. S. Albert, M. E. Reichman, W. S. Campbell, J. C. Barrett, S. D. Hursting, J. T. Judd, and P. R. Taylor Effects of Alcohol and Menstrual Cycle on Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2264 - 2267. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Lee, H. Moon, K.-H. Chun, Y.-S. Chang, K. Hassan, L. Ji, R. Lotan, F. R. Khuri, and W. K. Hong Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells J Natl Cancer Inst, October 20, 2004; 96(20): 1536 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ikezoe, S. Tanosaki, U. Krug, B. Liu, P. Cohen, H. Taguchi, and H. P. Koeffler Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells Blood, July 1, 2004; 104(1): 237 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, H. Zhao, K.-A. Do, M. M. Johnson, Q. Dong, W. K. Hong, and M. R. Spitz Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer Clin. Cancer Res., June 15, 2004; 10(12): 3988 - 3995. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Oh, W. Wu, G. Tortolero-Luna, R. Broaddus, D. M. Gershenson, T. W. Burke, R. Schmandt, and K. H. Lu Increased Plasma Levels of Insulin-Like Growth Factor 2 and Insulin-Like Growth Factor Binding Protein 3 Are Associated with Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 748 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Decensi, U. Veronesi, R. Miceli, H. Johansson, L. Mariani, T. Camerini, M. G. Di Mauro, E. Cavadini, G. De Palo, A. Costa, et al. Relationships between Plasma Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 and Second Breast Cancer Risk in a Prevention Trial of Fenretinide Clin. Cancer Res., October 15, 2003; 9(13): 4722 - 4729. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mao, S. Pan, S. W. Wen, and K. C. Johnson Physical Activity and the Risk of Lung Cancer in Canada Am. J. Epidemiol., September 15, 2003; 158(6): 564 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Liu, F. Lian, D. E. Smith, R. M. Russell, and X.-D. Wang Lycopene Supplementation Inhibits Lung Squamous Metaplasia and Induces Apoptosis via Up-Regulating Insulin-like Growth Factor-binding Protein 3 in Cigarette Smoke-exposed Ferrets Cancer Res., June 15, 2003; 63(12): 3138 - 3144. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Spitz, M. J. Barnett, G. E. Goodman, M. D. Thornquist, X. Wu, and M. Pollak Serum Insulin-like Growth Factor (IGF) and IGF-binding Protein Levels and Risk of Lung Cancer: A Case-Control Study Nested in the {beta}-Carotene and Retinol Efficacy Trial Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1413 - 1418. [Abstract] [Full Text] [PDF] |
||||









